Progress in the treatment of ocular graft-versus-host disease

Authors: Sun Suhua,  Hong Jing
DOI: 10.3760/cma.j.cn115989-20210922-00525
Published 2022-03-10
Cite asChin J Exp Ophthalmol, 2022, 40(3): 280-283.

Abstract

Allogeneic hematopoietic stem cell transplantation is an effective therapy for the treatment of hematological benign and malignant tumors, but the occurrence of graft-versus-host disease (GVHD) will affect the whole organs and tissues, causing serious damages to the patient’s body.This not only seriously affects the life quality of patients, but also increases the mortality of patients after transplantation.Ocular GVHD is a manifestation of ocular rejection, and 60%-90% of patients with chronic GVHD are accompanied by ocular GVHD, the manifestations of which are dry eye, conjunctivitis, keratitis, and so on.Severe ocular GVHD can cause vision loss.But there is no unified treatment standard at present.The commonly used treatments include artificial tears, autologous serum eye drops, topical glucocorticoid, topical immunosuppressive agents, punctal occlusion, and contact lens wearing.The treatment progress of ocular GVHD was reviewed in this article.

Key words:

Hematopoietic stem cell transplantation, allogeneic; Graft versus host disease, ocular; Therapy

Contributor Information

Sun Suhua

Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, China

Sun Suhua is working at the Department of Otorhinolaryngology Head and Neck Surgery, Peking University Third Hospital, Beijing 100191, China

Hong Jing

Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, China

(Read 6 times, 1 visits today)